We noticed you're browsing in private or incognito mode.

To continue reading this article, please exit incognito mode or log in.

Not an Insider? Subscribe now for unlimited access to online articles.

Rewriting Life

DNA Drugs

Using DNA to rev up the immune system.

Turning DNA into a therapeutic treatment usually means delivering the genetic material directly into cells where it can act as native DNA does, coding for needed proteins. Now researchers are using DNA in a new class of drugs that rev up the immune system, potentially helping to boost vaccines’ power and even to fight cancer-all without ever entering a cell.

The new drugs consist of short synthetic DNA segments that mimic gene sequences found only in bacteria. The segments bind to receptors on the surface of immune cells; the cells interpret the molecules as signs of a bacterial infection and respond by ramping up the body’s defenses. The first use of the technology in humans is likely to be with vaccines, in order to boost the immune system’s response to inoculation, says Ethan Shevach, an immunologist at the National Institute of Allergy and Infectious Diseases. In tests on animals, the DNA segments are “unbelievably good,” Shevach says.

Dynavax in Emeryville, CA, has completed early human-safety trials of an immune-stimulating DNA sequence, which when combined with a standard hepatitis B vaccine, seems to help the vaccine take effect faster and with fewer injections. Because slightly different DNA sequences may preferentially trigger specific elements of the immune system, the drugs can be tailored for particular uses such as activating natural killer cells, which attack cancerous cells. Shevach believes that the DNA fragment technology “will have a greater use [with] vaccines than as a stand-alone drug,” but even that would be greatly welcomed by researchers.

This story is part of our November 2002 Issue
See the rest of the issue
Coley Pharmaceutical (Wellesley, MA) Alergies, asthma, hepatitis B Human trials
Dynavax (Emeryville, CA) Allergies, cancer, hepatitis B Human trials
Hybridon (Cambridge, MA) Cancer Animal Research

AI is here.
Own what happens next at EmTech Digital 2019.

Register now
More from Rewriting Life

Reprogramming our bodies to make us healthier.

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus the digital magazine, extensive archive, ad-free web experience, and discounts to partner offerings and MIT Technology Review events.

    See details+

    Print + Digital Magazine (6 bi-monthly issues)

    Unlimited online access including all articles, multimedia, and more

    The Download newsletter with top tech stories delivered daily to your inbox

    Technology Review PDF magazine archive, including articles, images, and covers dating back to 1899

    10% Discount to MIT Technology Review events and MIT Press

    Ad-free website experience

You've read of three free articles this month. for unlimited online access. You've read of three free articles this month. for unlimited online access. This is your last free article this month. for unlimited online access. You've read all your free articles this month. for unlimited online access. You've read of three free articles this month. for more, or for unlimited online access. for two more free articles, or for unlimited online access.